AtriCure Statistics
Total Valuation
AtriCure has a market cap or net worth of $2.89 billion. The enterprise value is $2.80 billion.
| Market Cap | 2.89B |
| Enterprise Value | 2.80B |
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AtriCure has 50.92 million shares outstanding. The number of shares has increased by 3.13% in one year.
| Current Share Class | 50.92M |
| Shares Outstanding | 50.92M |
| Shares Change (YoY) | +3.13% |
| Shares Change (QoQ) | +1.97% |
| Owned by Insiders (%) | 3.98% |
| Owned by Institutions (%) | 108.74% |
| Float | 48.89M |
Valuation Ratios
The trailing PE ratio is 185.09 and the forward PE ratio is 167.97.
| PE Ratio | 185.09 |
| Forward PE | 167.97 |
| PS Ratio | 4.91 |
| Forward PS | 4.38 |
| PB Ratio | 5.43 |
| P/TBV Ratio | 11.24 |
| P/FCF Ratio | 54.68 |
| P/OCF Ratio | 42.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 73.41, with an EV/FCF ratio of 52.97.
| EV / Earnings | 188.42 |
| EV / Sales | 4.75 |
| EV / EBITDA | 73.41 |
| EV / EBIT | 164.62 |
| EV / FCF | 52.97 |
Financial Position
The company has a current ratio of 4.33, with a Debt / Equity ratio of 0.18.
| Current Ratio | 4.33 |
| Quick Ratio | 3.13 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 2.41 |
| Debt / FCF | 1.83 |
| Interest Coverage | 2.95 |
Financial Efficiency
Return on equity (ROE) is 2.95% and return on invested capital (ROIC) is 3.62%.
| Return on Equity (ROE) | 2.95% |
| Return on Assets (ROA) | 1.57% |
| Return on Invested Capital (ROIC) | 3.62% |
| Return on Capital Employed (ROCE) | 2.69% |
| Weighted Average Cost of Capital (WACC) | 10.73% |
| Revenue Per Employee | $436,891 |
| Profits Per Employee | $11,024 |
| Employee Count | 1,350 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, AtriCure has paid $1.31 million in taxes.
| Income Tax | 1.31M |
| Effective Tax Rate | 8.11% |
Stock Price Statistics
The stock price has increased by +71.93% in the last 52 weeks. The beta is 1.21, so AtriCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | +71.93% |
| 50-Day Moving Average | 57.48 |
| 200-Day Moving Average | 39.09 |
| Relative Strength Index (RSI) | 46.55 |
| Average Volume (20 Days) | 790,421 |
Short Selling Information
The latest short interest is 4.89 million, so 9.60% of the outstanding shares have been sold short.
| Short Interest | 4.89M |
| Short Previous Month | 4.89M |
| Short % of Shares Out | 9.60% |
| Short % of Float | 10.00% |
| Short Ratio (days to cover) | 5.99 |
Income Statement
In the last 12 months, AtriCure had revenue of $589.80 million and earned $14.88 million in profits. Earnings per share was $0.31.
| Revenue | 589.80M |
| Gross Profit | 452.63M |
| Operating Income | 17.04M |
| Pretax Income | 16.20M |
| Net Income | 14.88M |
| EBITDA | 38.20M |
| EBIT | 17.04M |
| Earnings Per Share (EPS) | $0.31 |
Balance Sheet
The company has $187.03 million in cash and $96.83 million in debt, with a net cash position of $90.20 million or $1.77 per share.
| Cash & Cash Equivalents | 187.03M |
| Total Debt | 96.83M |
| Net Cash | 90.20M |
| Net Cash Per Share | $1.77 |
| Equity (Book Value) | 533.22M |
| Book Value Per Share | 10.47 |
| Working Capital | 279.42M |
Cash Flow
In the last 12 months, operating cash flow was $68.55 million and capital expenditures -$15.61 million, giving a free cash flow of $52.94 million.
| Operating Cash Flow | 68.55M |
| Capital Expenditures | -15.61M |
| Depreciation & Amortization | 21.16M |
| Net Borrowing | -2.18M |
| Free Cash Flow | 52.94M |
| FCF Per Share | $1.04 |
Margins
Gross margin is 76.74%, with operating and profit margins of 2.89% and 2.52%.
| Gross Margin | 76.74% |
| Operating Margin | 2.89% |
| Pretax Margin | 2.75% |
| Profit Margin | 2.52% |
| EBITDA Margin | 6.48% |
| EBIT Margin | 2.89% |
| FCF Margin | 8.98% |
Dividends & Yields
AtriCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.13% |
| Shareholder Yield | -3.13% |
| Earnings Yield | 0.54% |
| FCF Yield | 1.83% |
Analyst Forecast
The average price target for AtriCure is $64.89, which is 14.16% higher than the current price. The consensus rating is "Buy".
| Price Target | $64.89 |
| Price Target Difference | 14.16% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 12.72% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AtriCure has an Altman Z-Score of 6.49 and a Piotroski F-Score of 8.
| Altman Z-Score | 6.49 |
| Piotroski F-Score | 8 |